Status:
COMPLETED
Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics
Lead Sponsor:
University of Nevada, Reno
Collaborating Sponsors:
Renown Regional Medical Center
Conditions:
Clostridium Difficile Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a susp...
Detailed Description
This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a susp...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Previous CDI diagnosis
- Current admission with a suspected or a confirmed bacterial infection requiring antibiotics
Exclusion
- Active chronic diarrheal illness (eg, Crohn's disease, ulcerative colitis, short bowel syndrome)
- Previous adverse reactions to oral vancomycin
- Requiring metronidazole during hospitalization
- Known pregnancy
- Expected survival \<72 hours
- Patients receiving antibiotics only for surgical prophylaxis
- Patients who received prophylactic oral vancomycin for the current antibiotic course prior to enrollment in the study
Key Trial Info
Start Date :
March 8 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 17 2022
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT03466502
Start Date
March 8 2018
End Date
February 17 2022
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renown Regional Medical Center
Reno, Nevada, United States, 89502